Premium
Parameters for monitoring treatment effects in CIDP with anti‐MAG/SGPG IgM antibody
Author(s) -
Tagawa Yumi,
Yuki Nobuhiro,
Ohnishi Akio,
Hirata Koichi,
Hosokawa Shinichi
Publication year - 2001
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.1059
Subject(s) - medicine , chronic inflammatory demyelinating polyneuropathy , antibody , cyclophosphamide , immunology , titer , polyneuropathy , immunoglobulin m , gastroenterology , immunoglobulin g , chemotherapy
We used cycles of plasma exchange and intravenous cyclophosphamide to treat a patient who had chronic inflammatory demyelinating polyneuropathy with anti–myelin‐associated glycoprotein/sulfoglucuronylparagloboside IgM antibody. After treatment, serum anti‐sulfoglucuronylparagloboside IgM antibody titers were reduced significantly, and clear symptomatic improvement followed. The percentage of CD57‐positive lymphocytes and natural killer cell activity had also returned to normal. Our findings indicate that serial measurements of these parameters are useful for monitoring treatment effect in this disease. © 2001 John Wiley & Sons, Inc. Muscle Nerve 24: 701–704, 2001